Morgan Stanley cut shares of GoodRx (NASDAQ:GDRX) from an overweight rating to an equal weight rating in a report published on Wednesday morning, Analyst Ratings Network reports. Morgan Stanley currently has $36.00 price objective on the stock.

A number of other brokerages have also issued reports on GDRX. SVB Leerink initiated coverage on GoodRx in a research note on Monday, October 19th. They issued an outperform rating and a $61.00 target price for the company. The Goldman Sachs Group started coverage on GoodRx in a report on Monday, October 19th. They set a neutral rating and a $48.00 target price for the company. UBS Group started coverage on shares of GoodRx in a report on Monday, October 19th. They issued a buy rating and a $64.00 price target on the stock. Deutsche Bank Aktiengesellschaft decreased their price objective on shares of GoodRx from $50.00 to $31.00 and set a hold rating for the company in a research note on Wednesday. They noted that the move was a valuation call. Finally, Barclays started coverage on shares of GoodRx in a research note on Monday, October 19th. They issued an equal weight rating and a $53.00 price objective on the stock. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and seven have given a buy rating to the stock. The company has a consensus rating of Hold and an average target price of $50.85.

GDRX opened at $38.80 on Wednesday. The firm’s 50-day moving average is $49.89. GoodRx has a 52-week low of $33.51 and a 52-week high of $64.22.

GoodRx (NASDAQ:GDRX) last released its earnings results on Thursday, November 12th. The company reported $0.09 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.12. The company had revenue of $140.40 million for the quarter, compared to analysts’ expectations of $135.05 million. GoodRx’s revenue was up 37.9% on a year-over-year basis. Sell-side analysts forecast that GoodRx will post -0.2 EPS for the current year.

Large investors have recently bought and sold shares of the business. Spectrum Equity Management Inc. acquired a new position in shares of GoodRx during the third quarter valued at approximately $2,676,866,000. Morgan Stanley purchased a new stake in shares of GoodRx during the third quarter worth approximately $91,743,000. Dragoneer Investment Group LLC acquired a new position in GoodRx in the 3rd quarter valued at $72,280,000. BlackRock Inc. purchased a new position in GoodRx in the 3rd quarter valued at $61,936,000. Finally, JPMorgan Chase & Co. acquired a new stake in GoodRx during the 3rd quarter worth $49,466,000.

GoodRx Company Profile

GoodRx Holdings, Inc is a holding company. The company, through its subsidiaries, owns and operates a prescription drug price comparison platform using data from local and mail-order pharmacies in the United States. It also provides pharmacy coupons to customers. The company offers generic and brand name pricing; alerts clients on manufacturer co-pay cards, pharmacy discounts, and state discount programs; and provides tips on slashing drug prices.

Featured Article: Cost of Debt

Analyst Recommendations for GoodRx (NASDAQ:GDRX)

Receive News & Ratings for GoodRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx and related companies with MarketBeat.com's FREE daily email newsletter.